CLL | Tumor

For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment

January 18th 2021, 4:00pm

Video

In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.

Areas Patients with CLL Can Focus On to Maintain Their Health Beyond Treatment

January 15th 2021, 10:00pm

Video

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.

Adding Copiktra to Standard of Care Chemotherapy Combination in CLL Could Improve Outcomes, But Not Without Toxicities

January 14th 2021, 3:00pm

Video

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute in Boston discussed how the addition of Copiktra to a three-drug chemotherapy combination improved outcomes in patients with CLL, with more than half achieving complete remission.

The Treatment Journey of a Patient with CLL

December 31st 2020, 4:00pm

Podcast

In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.

Early Use of Fixed-Duration Venclexta-Rituxan Combo in Patients with Relapsed/Refractory CLL Effective, And Does Not Compromise Subsequent Therapy Response in Patients Who Need Retreatment

December 14th 2020, 4:00pm

Article

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.

Venclexta Added to Novel Combination Therapy Elicits High Responses in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

December 14th 2020, 2:00pm

Article

Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.

Novel Combination Therapy Contributes to Additional Progression-Free Survival Benefit Compared With Chemoimmunotherapy in Patients with CLL

December 9th 2020, 2:00pm

Article

The combination of ublituximab and umbralisib, two novel compounds, was able to safely prolong progression-free survival with low rates of toxicities in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy regardless of prior treatment.

Calquence Use Associated With Limited Heart Toxicities in Patients With Chronic Lymphocytic Leukemia

December 8th 2020, 10:00pm

Article

At a median follow-up of 25.9 months, 17% of the patient population who received Calquence monotherapy experienced a cardiac toxicity of any severity, which led to treatment discontinuation in only seven patients.

Investigational CAR-T Cell Therapy Lisocabtagene Maraleucel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL

December 8th 2020, 7:00pm

Article

The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.

Imbruvica-Based Treatment Elicited Long-Term Survival Benefits in Subset of Patients With CLL Who Historically Have Poor Outcomes

December 7th 2020, 8:00pm

Video

Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.